IL161677D0 - Stable liquid pharmaceutical formulation of igg antibodies - Google Patents

Stable liquid pharmaceutical formulation of igg antibodies

Info

Publication number
IL161677D0
IL161677D0 IL16167702A IL16167702A IL161677D0 IL 161677 D0 IL161677 D0 IL 161677D0 IL 16167702 A IL16167702 A IL 16167702A IL 16167702 A IL16167702 A IL 16167702A IL 161677 D0 IL161677 D0 IL 161677D0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
igg antibodies
stable liquid
stable
Prior art date
Application number
IL16167702A
Original Assignee
Protein Design Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33750901P priority Critical
Application filed by Protein Design Labs filed Critical Protein Design Labs
Priority to PCT/US2002/036093 priority patent/WO2003039485A2/en
Publication of IL161677D0 publication Critical patent/IL161677D0/en

Links

IL16167702A 2001-11-08 2002-11-08 Stable liquid pharmaceutical formulation of igg antibodies IL161677D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33750901P true 2001-11-08 2001-11-08
PCT/US2002/036093 WO2003039485A2 (en) 2001-11-08 2002-11-08 Stable liquid pharmaceutical formulation of igg antibodies

Publications (1)

Publication Number Publication Date
IL161677D0 true IL161677D0 (en) 2004-09-27

Family

ID=23320826

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16167702A IL161677D0 (en) 2001-11-08 2002-11-08 Stable liquid pharmaceutical formulation of igg antibodies
IL16167704A IL161677A (en) 2001-11-08 2004-04-29 Stable liquid pharmaceutical formuation comprising succinate buffer, polysorbate, sodium chloride and a daclizumab antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16167704A IL161677A (en) 2001-11-08 2004-04-29 Stable liquid pharmaceutical formuation comprising succinate buffer, polysorbate, sodium chloride and a daclizumab antibody

Country Status (16)

Country Link
US (3) US20030138417A1 (en)
EP (1) EP1441589B1 (en)
JP (2) JP5290489B2 (en)
KR (1) KR100913714B1 (en)
CN (1) CN1292655C (en)
AT (1) AT556591T (en)
AU (1) AU2002363339B2 (en)
CA (1) CA2466034C (en)
DK (1) DK1441589T3 (en)
ES (1) ES2392073T3 (en)
HK (1) HK1074750A1 (en)
IL (2) IL161677D0 (en)
LU (1) LU93314I2 (en)
NZ (1) NZ532896A (en)
PT (1) PT1441589E (en)
WO (1) WO2003039485A2 (en)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2423227C (en) * 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US20040208870A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
DK1691833T3 (en) * 2003-11-28 2010-05-03 Micromet Ag Compositions comprising polypeptides
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CN1956738B (en) * 2004-01-09 2013-05-29 辉瑞大药厂 Antibodies to MAdCAM
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd Ab humanised antibodies used in improving cognition
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (en) * 2005-01-28 2006-08-29 Formulation anti beta
AR062247A1 (en) * 2005-03-08 2008-10-29 Pharmacia & Upjohn Co Llc Compositions of anti-CTLA-4
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
JP5053264B2 (en) * 2005-05-19 2012-10-17 アムジェン インコーポレイテッド Compositions and methods for increasing antibody stability
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
US20070110757A1 (en) * 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
US20070190047A1 (en) * 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
JP2009503105A (en) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド Immune complex preparation
EP2354162A1 (en) * 2005-09-12 2011-08-10 Novimmune SA Anti-CD3 antibody formulations
KR101105871B1 (en) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 hFSF Aqueous Formulation
AU2006302254B2 (en) * 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
CN101378782A (en) * 2005-12-21 2009-03-04 惠氏公司 Protein formulations with reduced viscosity and uses thereof
CA2637726C (en) 2006-01-25 2014-04-15 Taro Pharmaceuticals North America, Inc. Anti-histamine compositions and use thereof
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc Inhibitor combinations angiopoietin-2 (ang2) inhibitor and the vascular endothelial growth factor (VEGF)
JP2009532474A (en) 2006-04-05 2009-09-10 アボツト・バイオテクノロジー・リミテツド Antibody purification
AU2007239679B2 (en) 2006-04-13 2012-10-11 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
AU2012200284B2 (en) * 2006-10-06 2014-03-06 Amgen Inc. Stable Antibody Formulations
CA2666492C (en) 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
US20100233759A1 (en) 2007-03-15 2010-09-16 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2010532790A (en) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Antibody prescription
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
EP2186905B1 (en) 2007-08-07 2016-07-13 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
RU2505603C2 (en) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Antibody against il-6 receptor
ES2595638T3 (en) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Method to modify the isoelectric point of an antibody by replacing amino acids in a CDR
MX2010003450A (en) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Modified antibody constant region.
BRPI0818039A2 (en) 2007-10-15 2014-10-14 Chugai Pharmaceutical Co Ltd Method for producing a capable of high-income hyperoprotein production cell.
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
CN101821403B (en) * 2007-10-24 2014-01-01 中外制药株式会社 Cell for use in the production of exogenous protein, and production process using the cell
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (en) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Liquid formulation containing a high concentration of antibody
EP2240156A2 (en) * 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
PE20110302A1 (en) * 2008-09-19 2011-05-21 Hoffmann La Roche pharmaceutical formulation of an antibody against P-selectin
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102301235B (en) * 2008-11-28 2014-11-19 Abbvie公司 Stable Antibody Compositions And Methods For Stabilizing Same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010102241A1 (en) * 2009-03-06 2010-09-10 Genentech, Inc. Antibody formulation
WO2010115728A2 (en) * 2009-03-30 2010-10-14 F. Hoffmann-La Roche Ag A method for avoiding glass fogging
WO2010123014A1 (en) 2009-04-22 2010-10-28 中外製薬株式会社 Method for preparing cell highly producing heterogeneous protein
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2726232A1 (en) * 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
US20110053209A1 (en) 2009-08-31 2011-03-03 Facet Biotech Corporation Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
DK2473528T3 (en) * 2009-09-03 2015-03-02 Ablynx Nv Stable formulations of polypeptides and uses thereof
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
WO2011028961A2 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
US20110104153A1 (en) 2009-10-30 2011-05-05 Facet Biotech Corporation Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP2519262A2 (en) * 2009-12-29 2012-11-07 F.Hoffmann-La Roche Ag Antibody formulation
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulations Stabilized liquid contentivas antibody
WO2011109452A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)
AU2011223805B2 (en) * 2010-03-01 2015-10-29 Cytodyn Inc. Concentrated protein formulations and uses thereof
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
FR2961107B1 (en) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Human immunoglobulin composition stabilized
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
JOP20180102A1 (en) 2010-09-30 2019-01-30 Ferring Bv Pharmaceutical composition
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
SG2014015069A (en) 2010-11-11 2014-07-30 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
TR201810703T4 (en) 2011-03-25 2018-08-27 Hoffmann La Roche New protein purification methods.
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Etanercept stable liquid formulation
AR086823A1 (en) 2011-06-30 2014-01-22 Genentech Inc Formulations of anti-c-met, methods
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
BR112014027372A2 (en) * 2012-05-03 2017-08-08 Boehringer Ingelheim Int anti-il-23p19 antibodies
MX2015000337A (en) * 2012-07-09 2015-09-25 Coherus Biosciences Inc Etanercept formulations exhibiting marked reduction in sub-visible particles.
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia Method for lowering the viscosity of high concentration protein solutions
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
TW201424749A (en) 2012-09-07 2014-07-01 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
RS59057B1 (en) * 2012-12-13 2019-08-30 Merck Sharp & Dohme Solution formulations of engineered anti-il-23p19 antibodies
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
AU2014233503A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
AU2014229282B2 (en) 2013-03-15 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
CN103217525B (en) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 Composition for improving cystatin C latex coated antibody stability, stabilizer containing the same, preparation method and application thereof
KR20140119396A (en) 2013-03-29 2014-10-10 삼성전자주식회사 Liquid formulation containing a protein drug
MX2016006488A (en) 2013-11-21 2016-08-03 Genmab As Antibody-drug conjugate lyophilised formulation.
CA2946230A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
TW201601756A (en) * 2014-05-16 2016-01-16 葛蘭素史克智慧財產管理有限公司 Antibody formulation
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
EP3157942A1 (en) 2014-06-23 2017-04-26 Novartis AG Site specific protein modifications
US20160030585A1 (en) 2014-06-23 2016-02-04 Novartis Ag Novel fatty acids and their use in conjugation to biomolecules
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
AR101753A1 (en) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPOUND OBJECTIVE IL-23A and TNF-a AND USE OF THE SAME
WO2016065090A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
CU20170093A7 (en) 2015-01-23 2017-09-06 Novartis Ag Conjugates of synthetic fatty acids and longer half-life apelin
AR104847A1 (en) * 2015-06-17 2017-08-16 Lilly Co Eli Formulation of anti-CGRP antibody
CN108367053A (en) 2015-12-22 2018-08-03 诺华股份有限公司 The method that metabolic disease is treated or improved using growth and differentiation factor 15 (GDF-15)
BR112018014277A2 (en) 2016-01-13 2018-12-18 Genmab As formulation, and method of preparing an injectable solution of an axl-adc
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
BR112019007858A2 (en) 2016-10-21 2019-07-02 Amgen Inc pharmaceutical formulations and methods for producing the same
KR20180046888A (en) 2016-10-28 2018-05-09 (주)셀트리온 Stable Pharmaceutical Formulation
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
TW201929893A (en) 2017-12-22 2019-08-01 瑞士商諾華公司 Methods of treating metabolic disorders with FGF21 variants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
EP0448605A4 (en) * 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
EP2275119B1 (en) * 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (en) * 1996-11-19 1998-07-15 Boehringer Mannheim Gmbh Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
KR20130105766A (en) 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 Human antibodies that bind human il-12 and methods for producing
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2423227C (en) * 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Also Published As

Publication number Publication date
CN1612689A (en) 2005-05-04
KR100913714B1 (en) 2009-08-24
JP5290489B2 (en) 2013-09-18
LU93314I2 (en) 2019-11-20
KR20050044365A (en) 2005-05-12
CA2466034C (en) 2012-12-18
HK1074750A1 (en) 2007-06-08
AT556591T (en) 2012-05-15
EP1441589B1 (en) 2012-05-09
US20110070231A1 (en) 2011-03-24
CN1292655C (en) 2007-01-03
WO2003039485A2 (en) 2003-05-15
ES2392073T3 (en) 2012-12-04
EP1441589A4 (en) 2007-07-04
US20110318343A1 (en) 2011-12-29
IL161677A (en) 2010-06-16
WO2003039485A3 (en) 2004-02-12
PT1441589E (en) 2012-08-13
JP2005508981A (en) 2005-04-07
US20030138417A1 (en) 2003-07-24
AU2002363339B2 (en) 2008-02-07
DK1441589T3 (en) 2012-08-06
US8465739B2 (en) 2013-06-18
NZ532896A (en) 2007-08-31
CA2466034A1 (en) 2003-05-15
JP2011068675A (en) 2011-04-07
EP1441589A2 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
IL209010D0 (en) Use of tnfalpha antibodies and another drug
HK1145992A1 (en) Stabilized liquid anti-rsv antibody formulations rsv
DK1432408T3 (en) Pharmaceutical compositions containing colloidal silica
DK1441790T3 (en) Package containing drug and dispenser
DE60224556D1 (en) Pump for dispensing dosed quantities of two or more substances
GC0000307A (en) Pyrimidone compounds and pharmaceutical composition containing them
HRP20140267T1 (en) Liquid stabilized protein formulations in coated pharmaceutical containers
DE60239067D1 (en) Preparation of display changes
DE60128542D1 (en) Nitrogenic cyclic compounds and pharmaceutical preparations containing them
IL204031A (en) Use of an anti-cd40 antibody and anti-cd20 antibody for the preparation of medicaments for treating autoimmune diseases
DK1157042T3 (en) Preparation of tetravalent antibodies
PT1439829E (en) Medication containing 3- (3-dimethylamino-1-ethyl-2-methylpropyl) -ophenol providing delayed release of the active substance
DE60230262D1 (en) Carboxylene derivatives and these drugs containing active substance
AU2002256025A1 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
DE60234825D1 (en) Drugs container
HU0303128A3 (en) Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it
PT1207866E (en) Form of delayed administration containing tramadol sacarinate
DE60224111D1 (en) Kit for the preparation of a dosage form for delivering a bioactive substance
AU7659801A (en) Liquid formulation of metformin
DK1458377T3 (en) Pharmaceutical compositions containing tegaserod
EP1372718A4 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
HU0401116A3 (en) Stable liquid peticide compositions
AT500818T (en) Calciumator vastatin containing medicine preormulation
AT428439T (en) Liquid composition of factor vii polypeptides
DE60138948D1 (en) Medical aerosol formulation of antidiabetika